152 related articles for article (PubMed ID: 10516693)
41. [High-dose chemotherapy with autologous peripheral blood stem cell transplantation (PBSCT) for refractory bone and soft tissue sarcomas].
Yonemoto T; Tatezaki S; Ishii T; Satoh T
Gan To Kagaku Ryoho; 1999 Sep; 26(10):1431-5. PubMed ID: 10500530
[TBL] [Abstract][Full Text] [Related]
42. Sequential intensified conditioning and tapering of prophylactic immunosuppressants for graft-versus-host disease in allogeneic hematopoietic stem cell transplantation for refractory leukemia.
Liu QF; Fan ZP; Zhang Y; Jiang ZJ; Wang CY; Xu D; Sun J; Xiao Y; Tan H
Biol Blood Marrow Transplant; 2009 Nov; 15(11):1376-85. PubMed ID: 19822296
[TBL] [Abstract][Full Text] [Related]
43. Topotecan combined with myeloablative doses of thiotepa and carboplatin for neuroblastoma, brain tumors, and other poor-risk solid tumors in children and young adults.
Kushner BH; Cheung NK; Kramer K; Dunkel IJ; Calleja E; Boulad F
Bone Marrow Transplant; 2001 Sep; 28(6):551-6. PubMed ID: 11607767
[TBL] [Abstract][Full Text] [Related]
44. Outpatient sequential high dose alkylation with stem cell support for patients with advanced breast cancer: a phase I-II study.
Genre D; Viens P; Gravis G; Bertucci F; Cowen D; Novakovitch G; Derméche S; Chabannon C; Oziel-Taieb S; Camerlo J; Houvenaeghel G; Jacquemier J; Maraninchi D
Anticancer Res; 2000; 20(3B):2033-40. PubMed ID: 10928147
[TBL] [Abstract][Full Text] [Related]
45. Immune reconstitution following allogeneic stem cell transplantation in recipients conditioned by low intensity vs myeloablative regimen.
Morecki S; Gelfand Y; Nagler A; Or R; Naparstek E; Varadi G; Engelhard D; Akerstein A; Slavin S
Bone Marrow Transplant; 2001 Aug; 28(3):243-9. PubMed ID: 11535991
[TBL] [Abstract][Full Text] [Related]
46. Feasibility and low toxicity of early radiotherapy after high-dose chemotherapy and autologous stem cell transplantation for patients with high-risk stage II-III and locally advanced breast carcinoma.
Stemmer SM; Pfeffer MR; Rizel S; Hardan I; Goffman J; Gezin A; Neumann A; Kitsios P; Alezra D; Brenner HJ
Cancer; 2001 Jun; 91(11):1983-91. PubMed ID: 11391576
[TBL] [Abstract][Full Text] [Related]
47. Veno-occlusive disease of the liver after high-dose cytoreductive therapy with busulfan and melphalan for autologous blood stem cell transplantation in multiple myeloma patients.
Carreras E; Rosiñol L; Terol MJ; Alegre A; de Arriba F; García-Laraña J; Bello JL; García R; León A; Martínez R; Peñarrubia MJ; Poderós C; Ribas P; Ribera JM; San Miguel J; Bladé J; Lahuerta JJ;
Biol Blood Marrow Transplant; 2007 Dec; 13(12):1448-54. PubMed ID: 18022574
[TBL] [Abstract][Full Text] [Related]
48. Mobilization strategies for the collection of peripheral blood progenitor cells: Results from a pilot study of delayed addition G-CSF following chemotherapy and review of the literature.
Jacoub JF; Suryadevara U; Pereyra V; Colón D; Fontelonga A; Mackintosh FR; Hall SW; Ascensão JL
Exp Hematol; 2006 Nov; 34(11):1443-50. PubMed ID: 17046563
[TBL] [Abstract][Full Text] [Related]
49. Immune reconstitution after autologous hematopoietic stem cell transplantation in relation to underlying disease, type of high-dose therapy and infectious complications.
Steingrimsdottir H; Gruber A; Björkholm M; Svensson A; Hansson M
Haematologica; 2000 Aug; 85(8):832-8. PubMed ID: 10942930
[TBL] [Abstract][Full Text] [Related]
50. Idiopathic pneumonia syndrome after high-dose chemotherapy and autologous hematopoietic stem cell transplantation for high-risk breast cancer.
Wong R; Rondon G; Saliba RM; Shannon VR; Giralt SA; Champlin RE; Ueno NT
Bone Marrow Transplant; 2003 Jun; 31(12):1157-63. PubMed ID: 12796796
[TBL] [Abstract][Full Text] [Related]
51. Varicella zoster virus infection associated with high-dose chemotherapy and autologous stem-cell rescue.
Bilgrami S; Chakraborty NG; Rodriguez-Pinero F; Khan AM; Feingold JM; Bona RD; Edwards RL; Dorsky D; Clive J; Mukherji B; Tutschka PJ
Bone Marrow Transplant; 1999 Mar; 23(5):469-74. PubMed ID: 10100561
[TBL] [Abstract][Full Text] [Related]
52. High dose mitoxantrone with thiotepa, cyclophosphamide and autologous stem cell rescue for high risk stage II and stage III breast cancer. German GABG-4/EH-93-Study.
Zander AR; Krüger W; Kröger N; Damon L; Königmann M; Berdel WE; Gieseking F; Schäfer-Eckart K; Möbus V; Frickhofen N; Wandt H; Illiger HJ; Metzner B; Kolbe K; Wörmann B; Trümper L; Huber C; Hossfeld DK; Maass H; Jonat W
Bone Marrow Transplant; 1996 Sep; 18 Suppl 1():S24-5. PubMed ID: 8899165
[No Abstract] [Full Text] [Related]
53. [High-dose chemotherapy with autologous peripheral blood stem cell transplantation support in a patient with breast cancer metastasis to bone marrow: immunocytochemical monitoring of cancer-cell contamination].
Uno H; Fujita M; Hino N; Nakagawa H; Miyagawa H; Aoki J; Taniyama K; Sasaki N
Rinsho Ketsueki; 1999 Jul; 40(7):556-62. PubMed ID: 10483138
[TBL] [Abstract][Full Text] [Related]
54. Minimal toxicity and mortality in high-risk breast cancer patients receiving high-dose cyclophosphamide, thiotepa, and carboplatin plus autologous marrow/stem-cell transplantation and comprehensive supportive care.
Holland HK; Dix SP; Geller RB; Devine SM; Heffner LT; Connaghan DG; Hillyer CD; Hughes LL; Miller RL; Moore MR; Winton EF; Wingard JR
J Clin Oncol; 1996 Apr; 14(4):1156-64. PubMed ID: 8648370
[TBL] [Abstract][Full Text] [Related]
55. Autologous platelet collection and storage to support thrombocytopenia in patients undergoing high-dose chemotherapy and circulating progenitor cell transplantation for high-risk breast cancer.
Torretta L; Perotti C; Pedrazzoli P; Dornini G; Viarengo G; Livraghi A; Noris P; Da Prada GA; Balduini CL; della Cuna GR; Salvaneschi L
Vox Sang; 1998; 75(3):224-9. PubMed ID: 9852411
[TBL] [Abstract][Full Text] [Related]
56. Excessive toxicity of once daily i.v. BU, melphalan and thiotepa followed by auto SCT on patients with non-Hodgkin's lymphoma.
Lee SC; Kim SJ; Lee DH; Kim WS; Suh C; Won JH
Bone Marrow Transplant; 2010 Apr; 45(4):801-2. PubMed ID: 19767780
[No Abstract] [Full Text] [Related]
57. High-dose chemotherapy with autologous stem cell support for breast cancer: a review of the Dana-Farber Cancer Institute/Beth Israel Hospital experience.
Ayash LJ; Elias A; Wheeler C; Tepler I; Schwartz G; Schnipper L; Frei E; Antman K
J Hematother; 1993; 2(4):507-11. PubMed ID: 7916250
[TBL] [Abstract][Full Text] [Related]
58. High-dose busulfan, melphalan, thiotepa and peripheral blood stem cell infusion for the treatment of metastatic breast cancer.
Bensinger WI; Schiffman KS; Holmberg L; Appelbaum FR; Maziarz R; Montgomery P; Ellis E; Rivkin S; Weiden P; Lilleby K; Rowley S; Petersdorf S; Klarnet JP; Nichols W; Hertler A; McCroskey R; Weaver CH; Buckner CD
Bone Marrow Transplant; 1997 Jun; 19(12):1183-9. PubMed ID: 9208111
[TBL] [Abstract][Full Text] [Related]
59. Incidence and outcome of Clostridium difficile infection following autologous peripheral blood stem cell transplantation.
Bilgrami S; Feingold JM; Dorsky D; Edwards RL; Bona RD; Khan AM; Rodriguez-Pinero F; Clive J; Tutschka PJ
Bone Marrow Transplant; 1999 May; 23(10):1039-42. PubMed ID: 10373070
[TBL] [Abstract][Full Text] [Related]
60. Dose intensive therapy with autologous blood stem cell transplantation in breast cancer.
Kotasek D; Sage RE; Dale BM; Norman JE; Bolton A
Aust N Z J Med; 1994 Jun; 24(3):288-95. PubMed ID: 7980212
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
